AI API calls are expensive. After our always-on bot burned through tokens, we found seven optimization levers that cut costs by 45-50% without sacrificing output quality.
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results